Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community‐based, randomized study
- 20 December 2006
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 99 (4), 836-844
- https://doi.org/10.1111/j.1464-410x.2006.06658.x
Abstract
To assess health-related quality-of-life (HRQoL) and safety with the oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA) in the Multicentre Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin (MATRIX) study, as HRQoL measurements are increasingly important in evaluating pharmacotherapy for overactive bladder (OAB).This randomized, open-label, community-based study enrolled 2878 participants aged >/=18 years who had been given a diagnosis of OAB. The 327 study sites were representative of various practice types. All participants were treated with OXY-TDS 3.9 mg/day for /= 4 on a scale of 1-6), and most (1632/2859; 57.1%) had been given previous drug treatment for OAB. Of 2592 with evaluable baseline KHQ scores, 92.2% reported urgency and 88.2% reported urge urinary incontinence. The most impaired domains at baseline were Incontinence Impact (69.3), Symptom Severity (55.9), and Sleep/Energy (54.2). There were clinically meaningful and statistically significant improvements in nine of 10 domains at the study end; the greatest improvements were in Incontinence Impact (-13.5), Symptom Severity (-12.4), and Role Limitations (-13.3). The treatment was well tolerated, with low incidences of drug-related anticholinergic adverse effects such as dry mouth (75; 2.6%), constipation (44; 1.5%), and dizziness (21; 0.7%). There were drug-related application-site reactions, including pruritus, erythema, dermatitis and irritation, in 14.0% of participants.OXY-TDS treatment was well tolerated in this diverse, community-based population, and resulted in clinically significant improvements in HRQoL, regardless of baseline characteristics.Keywords
This publication has 27 references indexed in Scilit:
- Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinenceNeurourology and Urodynamics, 2006
- Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid ProgramValue in Health, 2005
- Improved quality of life in patients with overactive bladder symptoms treated with solifenacinBJU International, 2004
- The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged womenInternational Journal Of Impotence Research, 2004
- How much is enough and who says so?BJOG: An International Journal of Obstetrics and Gynaecology, 2004
- Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary IncontinenceJournal of Urology, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- A SHORT-TERM, MULTICENTER, RANDOMIZED DOUBLE-BLIND DOSE TITRATION STUDY OF THE EFFICACY AND ANTICHOLINERGIC SIDE EFFECTS OF TRANSDERMAL COMPARED TO IMMEDIATE RELEASE ORAL OXYBUTYNIN TREATMENT OF PATIENTS WITH URGE URINARY INCONTINENCEJournal of Urology, 2001
- Quality‐of‐life aspects of the overactive bladder and the effect of treatment with tolterodineBJU International, 1999
- The Influence of Urinary Incontinence on the Quality of Life of Elderly WomenAge and Ageing, 1993